A t(5;12)(q33;p13) translocation is a recurrent chromosome abnormality in a subgroup of myeloid malignancies with features of both myeloproliferative disorders and myelodysplastic syndromes (MDSs). The molecular consequence of a t(5;12) is a fusion between the platelet-derived growth factor receptor-B gene on chromosome 5 and a novel ETS-like gene, TEL. on chromosome 12. We report on three patients with a t(5;12)(q33;p13) diagnosed as chronic myelomonocytic leukemia, and one case of a t(10;12)(q24;p13) in a progressive MDS, with eosinophilia and monocytosis. Involvement of the TEL gene in these chromosome translocations was investigated by fluorescence in situ hybridization (FISH) with cosmid probes containing selectively the 5' end or 3' end of TEL. Hybridization of these cosmids t o a der(5)/ der(l0) or a der(l2). respectively, demonstrated a rearrangement of TEL in both translocations, showing that the t(10;12) is a variant translocation of the t(5;12). Cloning of the fusion cDNA of one case of t(5;12) showed that the LASSIFICATION OF myeloid leukemias that show features of both myeloproliferative and myelodysplastic disorders have been the subject of intensive discussion over the past few years.'" However, within this group of disorders, cytogenetic analysis showed at least one recurrent translocation, ie, a t(5;12)(q33;p13), among malignancies classified as Ph-negative chronic myeloid leukemia, myelodysplastic syndrome (MDS), atypical chronic myelomonocytic leukemia (CMML), or chronic myeloproliferative disThis t(5;12) translocation, which has been recently characterized at the molecular level, involves the plateletderived growth factor receptor-B (PDGFRB) gene at 5q33 and the TEL gene at 1 2~1 3 , which is a novel member of the ETS family." The translocation results in expression of a fusion transcript linking the 5' helix-loop-helix (HLH) domain of the TEL gene to the transmembrane and tyrosine kinase domains of PDGFRB.
breakpoint occurred at the RNA level at exactly the same position as reported by Golub et al (Cell 77:307, 1994 ). In addition, the TEL gene on chromosome 12 could be localized between two probes previously mapped to 12~13, namely PRBl and D12S178, leading t o a better definition of the position of TEL in this chromosome region. Moreover, in the case involving chromosome 10, the breakpoint occurred between cKTN206 and cKTN312/LYT-10 at 10q24. Clinicohematological data in these studies as well as the restriction mapping of chromosomal breakpoints strongly suggest that (1) common features in MDSs involving the TEL gene are monocytosis and eosinophilia, (2) chromosomes other than no. 5 may be involved and at least a t(10;12)(q24;p13) variant chromosome translocation does exist in these MDSs, and (3) both standard and variant 12p/TEL translocations may be identified by FISH with appropriate probes. 0 1995 by The American Society of Hematology.
We report here three patients with a typical t(5;12) (q33;p13) diagnosed as CMML according to the FrenchAmerican-British criteria and one case of refractory anemia (RA) with eosinophilia in the bone marrow (BM) and increasing monocytosis, associated with what appeared to be a variant t( 10;12)(q24;p13) translocation. We investigated the TEL gene in both types of translocations with Southern blotting and fluorescence in situ hybridization (FISH) analysis with cosmids specific for the 5' end and the 3' end of the TEL gene. Moreover, 1Oq was further analyzed with a panel of probes to better localize the breakpoint on 10q24.
MATERIALS AND METHODS

Patients.
The four patients involved in this study were collected from three centers: Centre for Human Genetics (Leuven, Belgium), case no. 1 ; Hospital de Sant Pau (Barcelona, Spain), case no. 2; and the Institute of Hematology (Perugia, Italy), cases no. 3 and 4. Clinical and hematologic findings are summarized in Table 1 .
Cytogenetics. Cytogenetic analyses from peripheral blood (PB) and BM were performed after 3 days using synchronized cultures without stimulation. R-andor G-chromosome banding was used. Karyotypes are presented in accordance with ISCN.14 DNA analysis.
The TEL cDNA was amplified from a liver cDNA sample using a 5'-CTCCAGAGAGCCCAGTGCCGAGT oligonucleotide as forward primer and a 5'-TCCAGACGGTCTCGGC-CACT oligonucleotide as reverse primer. The resulting 1.241-bp cDNA that contains the complete coding sequence of TEL was cloned into pGEM-3Z and was sequenced.
DNA was isolated from BM samples of patients no. 3 and 4 with conventional methods. DNA (15pg) was digested with EcoRI or Pst I, separated on an agarose gel, blotted onto a nylon membrane, and probed with the complete TEL cDNA.
Cosmids were isolated from the Lawrence Livermore (Livermore. CA) chromosome 12 library LL12NCO1 with the TEL cDNA as a probe. High-density filters of the library were kindly grown by Dr E. Schoenmakers ( Department of Molecular Oncology, Center for Human Genetics). Ten cosmids were isolated. Southern analysis of the cosmids was performed with four fragments of the TEL cDNA ranging from bp 79 to 371, bp 372 to 678, bp 679 to 1038, and bp 1039-1329 (numbering according to Golub et all3) and generated FISH experiments were evaluated on a Zeiss Axioplan fluorescence microscope (Zeiss, Oberkochen, Germany) and a Leitz DMRB (LDMRB) fluorescence microscope (E. Leitz Inc, Wetzlor, Germany) equipped with a cooled CCD camera (Photometrics, Stuttgart, Germany) run by Imagenetics software (Imagenetics, Stuttgart, Germany). Eight to twenty-five informative chromosome spreads were analyzed for each experiment.
RNA analysis. Total RNA was isolated from BM cells of patient no. 3 by the guanidiniudacid phenol method. Total RNA (5pg) was used for the synthesis of first-strand cDNA, primed with oligo(dT), using Moloney murine leukemia virus reverse transcriptase (GIBCO-BRL) in a volume of 20 pL. Five microliters of the reaction was used for polymerase chain reaction (PCR) analysis. The TEW PDGFRB fusion cDNA was amplified by nested PCR. For the TEL gene the primers were 5'-CCTCCAGAGAGCCCAGTGCCGAGT and 5'-TCAGGATGGAGGAAGACTCGA. For the PDGFRB gene the primers described by Golub et a l l 3 were used. The PCR products were cloned into Sm-I-digested pUC18, and 5 clones were sequenced on an automated sequencer (ALF; Pharmacia, Uppsala, Sweden).
RESULTS
Nature of the disease. Based on clinical and laboratory findings (splenomegaly, monocytosis, eosinophilia, and absence of Ph chromosome and breakpoint cluster region rearrangement), three of the four cases (no. 1 to 3) presented were diagnosed as CMML. The fourth case presented as MDS with pancytopenia and only 2% of blasts in the BM (RA). However, an increasing number of monocytes (20%) was detected in the PB 20 months after diagnosis, when blast cells increased to 25%. BM eosinophilia was also present from the beginning.
Cytogenetics. Cytogenetic analysis was performed at the time of diagnosis in three cases (no. 2 to 4) and 2 years after the first observation in patient no. 1. The t(5;12)(q33;p13) was found as the sole structural abnormality in two patients; one of them also had a t(5;12)-positive subclone with trisomy 21 (case no. 1). The karyotype from the third patient showed a more complex rearrangement concerning chromosomes 6 and 16, in addition to the t(5;12). The fourth case was characterized by a t(10;12)(q24;p13) as the sole chromosomal aberration detected in two consecutive BM samples, analyzed at the time of RA and 2 years later, when evolution of the disease to a CMML-like disorder was observed.
DNA and RNA analysis. The involvement of the TEL gene in the t(5;12) and t(10;12) was studied by Southern analysis and FISH with cosmids containing the 5' end or the 3' end of the TEL gene. To isolate these probes a TEL cDNA 
shown). Therefore, this probe contains no sequences derived upstream from the published breakpoint in TEL. Several cosmids containing TEL sequences between bp I87 and 1,039 were isolated. Because these cosmids showed no overlap with either cTEL5' or cTEL3' and because they contain inserts of approximately 40 kb, the genomic sequence between both cosmids must be at least 40 kb.
Southern hybridizations of genomic DNA isolated from a BM sample of patients no. 3 and 4 and digested with EcoRI and Pst I with the TEL cDNA did not show any rearranged fragments. FISH with cosmid probes hybridizing to the chromosome region 12p was performed on leukemic cells from all patients. Patient no. 4 was further investigated with cosmids covering 10q22.1 to 10q25.1 (Fig 1) . FISH with TELspecific cosmids showed that cTEL3' was present on the normal chromosome 12p and the der( 12) all in analyzed cases and was absent on the der(5) (patients no. 1 through 3) or the der(l0) (patient no. 4). The reverse was observed with probe cTEL5'. Signals were present on the normal chromosome 12p and the der(5) for patients no. 1 through 3 or the der(l0) for patient no. 4, but never on the der(l2) (Fig  2) . Among the other 12p cosmids used, von Willebrand factor and PRBl hybridized to the der(5)t(5;12), whereas hybridization signals from the KRAS2, D12S 1 19, and D12S178 were foundon theder(12)t(5;12). Forchromosome 10, two cosmids cKTN420 (lOq22.1) and cKTN206 (10q22.3-q23.1) mapped proximal to the breakpoint. The third probe, cKTN312 previously assigned by FISH to lOq24.3-q25.1, as well as a probe for LYT-10 mapped distal to the breakpoint. A fusion transcript of TEL and PDGFRB could be amplified from cDNA of patient no. 3 for which an RNA sample was available. Sequencing of the resulting cDNA showed that in this case the fusion occurred at the RNA level at exactly the same position as reported by Golub et all3 for their t(5;12) case. (q24;p13). In three cases diagnosis was compatible with CMML, whereas the fourth case with the cytogenetic variant t(10;12) had a RA, which later evolved to a CMML-like disorder with eosinophilia and monocytosis. The 5;12 translocation was described for the first time by Keene et al' in two patients characterized by eosinophilia and 12p abnormalities, diagnosed as eosinophilic leukemia and Ph-negative CML. An additional case was reported by Srivastava et a19 in which CMML was characterized by overexpression of the KRAS2 oncogene, assigned to 12~12. Six other cases of atypical CML, CMML with eosinophilia or myeloproliferative disorder with dyserythropoiesis and eosinophilia, and t The t(5;12) was recently cloned by Golub et al." The investigators showed that the translocation results in expression of a fusion transcript between a novel gene at 12~13, called TEL (for translocation, ets, leukemia), which is a member of the ETS family, and the PDGFRB gene at 5q33. The TELPDGFRB fusion includes the 5' HLH domain of TEL and the transmembrane and tyrosine kinase domains of PDGFRB. The mechanism of transformation by the TELPDGFRB fusion is not known. However, it is of interest that the recipmcal fusion transcript containing the TEL, DNA-binding domain is not expressed in leukemic cells; thmfore, the chimeric gene shows mainly the case of RA with monocytosis and fibrosis. Altogether, data from the literature, from our patients no. 1, 2, and 3, and the clinical evolution of case no. 4 allow us to conclude that the malignant disorder associated with a structural rearrangement on 12p13/TEL gene is characterized by a high number of monocytes (more than 8% of the differential count in PB) and BM eosinophilia (more than 5% in BM) and is consistent with diagnosis of CMML in the majority of cases. Cytogenetically the 1 2~1 3 involvement is usually because of a 5; 12 translocation. Moreover, for the first time a cytogenetic variant t(10;12)(q%;p13) translocation is shown. is not clear whether they used genomic or cDNA p b e s for the former analysis. Our results suggest that the brealrpoint on chromosome 12 may occur in an intron sequence of the TEL gene not detected by the applied combination of restriction enzymes and the "EL cDNA. The large genomic size of the "EL gene supports this hypothesis. In case no. 3, however, sequencing of the fusion cDNA showed that exactly the same fragments of the TEL and PDGFRE3 genes were fused as described by Golub et al,13 further supporting the hypothesis that in these cases the HLH domain of TEL might be of functional importance.
The FISH investigations in this study and the cDNA analysis of one case definitely p v e d that the bmkpints in both t(5;12) and t(10;12) occurred within the TEL gene. Indeed, the 3' end of the TEL gene is maintained on the d e~l 2 ) chromosome, whereas the 5' end of E L is translocated to the der(5) or the der(l0) in both the t(5;12) and the t(10;12) cases, respectively (Fig 2) . ' Ihus, hematologic features, karyotypic results, and molecular data are in keeping with the definition of 1012 translocation as a variant of t(5; 12). The involvement of another hypothetical gene within an intron of TEL in the case with t(1012) appears to be extremely unlikely. These results also show the usefulness of isolated TEL cosmids as p b e s for the analysis of the involvement of TEL gene in MDS. In addition, data are CoIlSistent with a pte1-5'TEG3'TEknt orientation for the TEL gene on chromosome 12 and a qter-SPDGFW3-3'PDGFRBcent orientation for the FDGFRB gene on chromosome 5.
Further analysis of the t(5;12) and a t(lQ12) with a panel of 12pspecific cosmids allowed us to determine the position of the brealrpoint, as well as of the TEL gene, between D12S178 and P M 1 loci at 12~13. With respect to chromosome 10, FISH analysis showed that the breakpoint occurred in a region flanked by cKTN206 and cKTN312LYT-10 at 1Oq24. Although the lOq24 chromosome region carries some genes that may play an important role in leukemogenesis and lymphomagenesis (namely TcL3 (HOXlI),'* LYT-lO,I9 and APO-liFASZo), no recurrent associations of 1Oq24 chromosomal abnormalities with myeloid disorders have been reported before. In summary, the findings discussed here show that the TEL gene may be activated not only by fusion with the PDGFRE3 gene on chromosome 5q33.1, but also by unknown sequences on 1Oq24, located upstream to LYT-10. Involvement of the TEL in pathogenesis of h4DS may be easily analyzed by FlSH with cosmids containing the 5' end and 3' end of TEL.
